All In Biotech

Drug Trial Radar · NCT01004861

Safety Study of PLX108-01 in Patients With Solid Tumors

A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients With Advanced, Incurable, Solid Tumors in Which the Target Kinases Are Linked to Disease Pathophysiology

Last checked: Nov 20, 2026Latest source record: Jan 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

132

Actual

Start

Oct 1, 2009

Primary completion

Jan 31, 2018

Study completion Oct 25, 2018

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Plexxikon
First posted
Oct 30, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity. The primary objective of this study is to evaluate the safety and pharmacokinetics of orally administered PLX3397 in patients with advanced, incurable, solid tumors in which these target kinases are linked to disease pathophysiology. The secondary objective is to measure the pharmacodynamic activity of PLX3397 via blood, plasma and urine biomarkers of Fms activity.

Conditions

  • Solid Tumor

Interventions

  • PLX3397Drug

    Capsules administered once or twice daily, continuous dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Summary of Derived Best Tumor Response Per the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 - Dose Escalation (Efficacy Evaluable Population)Time frame: Every 2 months beginning Cycle 3, Day 1 until disease progression (up to approximately 30 months postdose)
  2. Summary of Derived Best Tumor Response Per the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 - Dose Extension (Efficacy Evaluable Population)Time frame: Every 2 months beginning Cycle 3, Day 1 until disease progression (up to approximately 30 months postdose)
  3. Duration of Response (Efficacy Evaluable Population) - Dose ExtensionTime frame: From initial response until disease progression or death, up to approximately 30 months postdose
  4. Progression-free Survival (Efficacy Evaluable Population) - Dose ExtensionTime frame: From Cycle 1 Day 1 to disease progression or death
  5. Best Overall Tumor Response (PVNS Cohort) Per the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 - Dose ExtensionTime frame: Every 2 months beginning Cycle 3, Day 1 until disease progression
  6. Summary Statistics for Selected PLX3397 Pharmacokinetics Parameter Cmax, Study Day Cycle 1 Day 15, Stratified by Cohort - Dose EscalationTime frame: Cycle 1, Day 15
  7. Summary Statistics for Selected PLX3397 Pharmacokinetics Parameter Tmax, Study Day Cycle 1 Day 15, Stratified by Cohort - Dose EscalationTime frame: Cycle 1, Day 15
  8. Summary Statistics for Selected PLX3397 Pharmacokinetics Parameter Area Under the Curve (AUC0-24), Study Day Cycle 1 Day 15, Stratified by Cohort - Dose EscalationTime frame: Cycle 1, Day 15 (QD dosing: predose [morning] and 0.5, 1, 2, 4, and 8 hours postdose; BID dosing: predose [morning] and 1, 2, 4, and 7 hours postdose)
  9. Numeric Rating Scale (NRS) for PVNS Symptoms Sum of Scores Through Cycle 2 (Efficacy Evaluable Population) - Dose ExtensionTime frame: Baseline, Cycle 1 Day 15, Cycle 2, Cycle 3, Cycle 12, Cycle 24, Cycle 36, and Cycle 46 (each cycle was 28 days)

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth

    Scottsdale, Arizona

  • UCLA

    Los Angeles, California

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Memorial Sloan-Kettering Cancer Center (MSKCC)

    New York, New York

  • Pennsylvania Oncology Hematology Associates

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Vanderbilt-Ingram Medical Center

    Nashville, Tennessee

  • Texas Oncology, PA (North)

    Dallas, Texas

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Evergreen Hematology & Oncology

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.